Featured tickers: $ABBV $ACAD $AMGN $BDSI $BLUE $CAPR $CNAT $CXMI $DNDN $DVAX $FMI $GERN $GILD $HALO $JNJ $KITE $NUOT $OXGN $PBYI $PFE $RHHBY $RTRX $SNY $SRPT $TRGT
Note you can use the search box at the upper right to find all BiotechDueDiligence content related to a particular stock of interest.
My buddy snapped this gem this morning on his way to work. I had to share it for the veterans. pic.twitter.com/VJ0DmpvQzW
— Brandon Hayward (@VexTrades) November 12, 2014
Always good to see a presentation on pediatric neuroblastoma - I'm one of the 30 year survivors! #sitc2014
— Sally Church (@MaverickNY) November 8, 2014
WOW! RT @shaneblackmon: $DNDN files voluntary Chapter 11... massive fall from grace
— Bio Stocks™ (@BioStocks) November 10, 2014
.@kyleserikawa Seattle biotech job mkt already saturated from Amgen shutdown. I expect many DNDN refugees will migrate to SF and BOS
— Luke Timmerman (@ldtimmerman) November 10, 2014
Convertible debt for biotech companies without proven cash flow. When will people learn? Terrible idea
— Luke Timmerman (@ldtimmerman) November 10, 2014
$DVAX up 874% on DSMB news....lol jk reverse split
— Emory Redd (@Emory_R) November 10, 2014
In 2010, Dendreon and Sanofi CEO Viehbacher were darlings of pharma. Today I'm reading about Dendreon bankruptcy and how Viehbach got fired
— Shannon Pettypiece (@spettypi) November 10, 2014
Oh, and speaking of bad news: $HALO reduced its workforce by 13%, or 22 employees (this news was hidden halfway down the page).
— Brad Loncar (@bradloncar) November 10, 2014
$BDSI bought here for NDA submission possible by yr end, and P3 Clonidine data in 1Q '15, bio swing trade portfolio. Cheers.
— $$$ Money $$$ (@BiotechMoney18) November 11, 2014
Did someone leave $SRPT and start working at $ACAD. Companies that can't walk chew gum ... actually struggling to just walk
— Tyler (@tylerhcarter) November 11, 2014
Academia dings Industry for a culture of secrecy, and yet who's spazzing out over livetweeting conference talks?
— Ethan O. Perlstein (@eperlste) November 11, 2014
Handy chart from CS-Unpartnered late stage biotechs. Not comprehensive, but handy nevertheless pic.twitter.com/T3WsLuIWSF
— Vikram Khanna (@VikramKhanna_) November 12, 2014
important note from $BLUE earnings pr the two B-Thal patients remain transfusion independent
— Dan Rosenblum (@sharkbiotech) November 12, 2014
A 26% swing in $OXGN. It's 830am. The insanity of micro-cap Biotech.
— BioBounce.com (@BioBounce) November 12, 2014
@23aloha @hydrogenblimp BTW they've been traveling with bankers lately so wouldn't be surprised if they plan to raise more money.
— Brad Loncar (@bradloncar) November 12, 2014
@ianestepan It's related 2previously discussed Gilead Invincibility Block™. It's a powerful force, but it wears off eventually.
— Roy Friedman (@DewDiligence) November 12, 2014
Normally I don’t like internet lynch mobs but the responses to #OzsInBox are perfect and well deserved.
— Larry Husten (@cardiobrief) November 12, 2014
@GantosJ At least they do not have any delays to announce. That is an improvement and ACLF data within 6 weeks
— David Sobek (@dsobek) November 12, 2014
Why I love Shanghai: run into Ascletis CEO Jinzi Wu today at breakfast - get a 20 minute in-depth briefing on HCV in China ...
— Josh Berlin (@BioPharmaJosh) November 13, 2014
Tiny $CAPR has an excellent webcast setup where anybody can submit questions. All companies should do this! pic.twitter.com/BX69AEjoTO
— Brad Loncar (@bradloncar) November 12, 2014
$ACAD is shaking off the NDA delay.
— Brad Loncar (@bradloncar) November 13, 2014
Landing on comets is just like drug discovery - it takes a decade or two, a team of people and a ton of cash to test your hypothesis.
— Troy Edward Wilson (@troyewilson) November 13, 2014
. @jennmcnary son Austin is getting his first infusion of eteplirsen today. Fantastic news. He’s a great kid. Best of luck, Austin.
— Adam Feuerstein (@adamfeuerstein) November 12, 2014
@KidsDrDave you do realize that if EMRs were treated as medical devices they'd all be pulled from the market?
— Suburban Physician (@BurbDoc) November 13, 2014
$GERN @ScripMandy @JohnCFierce This deal is not typical $JNJ style esp because development costs for Ph2 MF/MDS studies will be shared 50/50
— Andy Biotech (@AndyBiotech) November 13, 2014
@adamfeuerstein I would say that after ASH last year there were higher expectations. Perhaps less after clinical halts.Long way to go $GERN
— j l (@lomu_j) November 13, 2014
Congratulate on the data? Really? $PBYI
— David Miller (@AlpineBV_Miller) November 13, 2014
@sharkbiotech @adamfeuerstein Exactly. Our trial failed our primary endpoint and a key secondary but we totally knew it would suck.
— David Sobek (@dsobek) November 13, 2014
The ironic thing about $RTRX's pipeline guidance for 2015 is that it's exactly the same as what they guided for 2014. No kidding.
— Brad Loncar (@bradloncar) November 13, 2014
The concept of $AMGN being a "lawfirm with fermenters" reminds me of the time $RHHBY was said to be a "bank with a pharma division"
— Jacob Plieth (@JacobEPVantage) November 13, 2014
@DewDiligence it seems 2b a good co, but long term I think they are competing w/ clinics, other co's, and voluntary/social/open initiatives.
— David Maizenberg (@biologypartners) November 13, 2014
One bright spot from the $NUOT 10Q, zero dilution since Q2 report. Basic share count identical on Nov. 6th to Aug 7th. $CMXI
— Jason Napodano, CFA (@JNapodano) November 14, 2014
$TRGT CFO resigns....NOOOOOO!!!!!
— zach (@zbiotech) November 14, 2014
$ACHN has been a yo-yo. I guess everything is great today.
— David Sobek (@dsobek) November 14, 2014
+ everyone else MT @adamfeuerstein When primary endpoint fails, all 2ndary endpoints become hypothesis generating -- Richard Pazdur. $PBYI
— Matthew Herper (@matthewherper) November 14, 2014
@adamfeuerstein so the only concern now is the complete lack of efficacy?
— David Sobek (@dsobek) November 14, 2014
Public Service Announcement: Today I will be sharing 13F filings that I find interesting. Please don't be stupid. Do your own due diligence.
— Emory Redd (@Emory_R) November 14, 2014